Figure 3.

Cost-effectiveness (Euro/QALY and Euro/LY) for the bivalent and quadrivalent HPV vaccine. Black: Euros per life year gained; red: Euros per quality-adjusted life years gained; circles: quadrivalent vaccine; squares: bivalent vaccine.

Westra et al. BMC Infectious Diseases 2013 13:75   doi:10.1186/1471-2334-13-75
Download authors' original image